JP2006509841A - 生物学的許容量が改善された造影剤配合物 - Google Patents
生物学的許容量が改善された造影剤配合物 Download PDFInfo
- Publication number
- JP2006509841A JP2006509841A JP2005508300A JP2005508300A JP2006509841A JP 2006509841 A JP2006509841 A JP 2006509841A JP 2005508300 A JP2005508300 A JP 2005508300A JP 2005508300 A JP2005508300 A JP 2005508300A JP 2006509841 A JP2006509841 A JP 2006509841A
- Authority
- JP
- Japan
- Prior art keywords
- tris
- formulation
- contrast agent
- iosimenol
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000009472 formulation Methods 0.000 title claims abstract description 39
- 239000002872 contrast media Substances 0.000 title claims abstract description 25
- 150000001412 amines Chemical class 0.000 claims abstract description 30
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 19
- 239000007983 Tris buffer Substances 0.000 claims description 58
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- DLPPIGPJCKKVBA-UHFFFAOYSA-N Iosimenol Chemical compound OCC(O)CNC(=O)C1=C(I)C(C(=O)N)=C(I)C(N(CC(O)CO)C(=O)CC(=O)N(CC(O)CO)C=2C(=C(C(=O)NCC(O)CO)C(I)=C(C(N)=O)C=2I)I)=C1I DLPPIGPJCKKVBA-UHFFFAOYSA-N 0.000 claims description 33
- 229950004246 iosimenol Drugs 0.000 claims description 33
- 239000000872 buffer Substances 0.000 claims description 29
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- -1 2,3-dihydroxypropylcarbamoyl Chemical group 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 229960004359 iodixanol Drugs 0.000 claims description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims 1
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
- 150000001735 carboxylic acids Chemical class 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- 238000006798 ring closing metathesis reaction Methods 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 239000011630 iodine Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 150000003858 primary carboxamides Chemical class 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960002603 iopromide Drugs 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43287902P | 2002-12-12 | 2002-12-12 | |
| US10/701,586 US7250153B2 (en) | 2002-12-12 | 2003-11-05 | Contrast media formulations having improved biological tolerance |
| PCT/US2003/035762 WO2004054637A2 (en) | 2002-12-12 | 2003-11-07 | Contrast media formulations having improved biological tolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509841A true JP2006509841A (ja) | 2006-03-23 |
| JP2006509841A5 JP2006509841A5 (https=) | 2006-12-14 |
Family
ID=34107426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005508300A Abandoned JP2006509841A (ja) | 2002-12-12 | 2003-11-07 | 生物学的許容量が改善された造影剤配合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7250153B2 (https=) |
| EP (1) | EP1575621B1 (https=) |
| JP (1) | JP2006509841A (https=) |
| KR (1) | KR101067159B1 (https=) |
| CN (1) | CN1738651A (https=) |
| AT (1) | ATE447416T1 (https=) |
| AU (1) | AU2003295442B2 (https=) |
| CA (1) | CA2509035C (https=) |
| CY (1) | CY1110105T1 (https=) |
| DE (1) | DE60329939D1 (https=) |
| DK (1) | DK1575621T3 (https=) |
| ES (1) | ES2333863T3 (https=) |
| IL (1) | IL169119A (https=) |
| NO (1) | NO332350B1 (https=) |
| NZ (1) | NZ541139A (https=) |
| PT (1) | PT1575621E (https=) |
| SI (1) | SI1575621T1 (https=) |
| WO (1) | WO2004054637A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013522344A (ja) * | 2010-03-23 | 2013-06-13 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 安定化ｘ線診断用組成物の製法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE529135T1 (de) * | 2004-03-11 | 2011-11-15 | Mallinckrodt Llc | Röntgenkontrastformulierung mit einem gemisch aus einem jodierten monomer und dimer |
| FR2899581B1 (fr) * | 2006-04-07 | 2008-06-27 | Guerbet Sa | Procede d'atomisation du ioxilan |
| EP2240432B1 (en) | 2008-01-14 | 2012-07-04 | Mallinckrodt LLC | Process for the preparation of iosimenol |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU523295B2 (en) | 1978-07-04 | 1982-07-22 | Nycomed Imaging As | X-ray contrast agent |
| US5698739A (en) * | 1989-07-05 | 1997-12-16 | Schering Aktiengesellschaft | Carboxamide non-ionic contrast media |
| AU6114396A (en) * | 1995-06-16 | 1997-01-15 | Biophysica Foundation | Formyl derivatives as nonionic contrast media |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
-
2003
- 2003-11-05 US US10/701,586 patent/US7250153B2/en not_active Expired - Lifetime
- 2003-11-07 EP EP03786628A patent/EP1575621B1/en not_active Expired - Lifetime
- 2003-11-07 ES ES03786628T patent/ES2333863T3/es not_active Expired - Lifetime
- 2003-11-07 SI SI200331689T patent/SI1575621T1/sl unknown
- 2003-11-07 CN CNA2003801090166A patent/CN1738651A/zh active Pending
- 2003-11-07 DE DE60329939T patent/DE60329939D1/de not_active Expired - Lifetime
- 2003-11-07 NZ NZ541139A patent/NZ541139A/en not_active IP Right Cessation
- 2003-11-07 JP JP2005508300A patent/JP2006509841A/ja not_active Abandoned
- 2003-11-07 WO PCT/US2003/035762 patent/WO2004054637A2/en not_active Ceased
- 2003-11-07 CA CA2509035A patent/CA2509035C/en not_active Expired - Lifetime
- 2003-11-07 DK DK03786628T patent/DK1575621T3/da active
- 2003-11-07 PT PT03786628T patent/PT1575621E/pt unknown
- 2003-11-07 AT AT03786628T patent/ATE447416T1/de active
- 2003-11-07 AU AU2003295442A patent/AU2003295442B2/en not_active Ceased
- 2003-11-07 KR KR1020057010571A patent/KR101067159B1/ko not_active Expired - Fee Related
-
2005
- 2005-06-09 IL IL169119A patent/IL169119A/en active IP Right Grant
- 2005-07-08 NO NO20053343A patent/NO332350B1/no not_active IP Right Cessation
-
2010
- 2010-02-01 CY CY20101100092T patent/CY1110105T1/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013522344A (ja) * | 2010-03-23 | 2013-06-13 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 安定化ｘ線診断用組成物の製法 |
| US11185598B2 (en) | 2010-03-23 | 2021-11-30 | Ge Healthcare As | Preparation of stabilised x-ray diagnostic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| IL169119A0 (en) | 2007-07-04 |
| DE60329939D1 (de) | 2009-12-17 |
| CN1738651A (zh) | 2006-02-22 |
| DK1575621T3 (da) | 2009-12-14 |
| EP1575621B1 (en) | 2009-11-04 |
| PT1575621E (pt) | 2009-11-13 |
| NZ541139A (en) | 2008-07-31 |
| SI1575621T1 (sl) | 2010-01-29 |
| AU2003295442B2 (en) | 2008-11-06 |
| NO20053343L (no) | 2005-09-08 |
| ATE447416T1 (de) | 2009-11-15 |
| NO332350B1 (no) | 2012-09-03 |
| KR20050088312A (ko) | 2005-09-05 |
| WO2004054637A3 (en) | 2004-09-16 |
| CA2509035A1 (en) | 2004-07-01 |
| EP1575621A4 (en) | 2008-11-26 |
| ES2333863T3 (es) | 2010-03-02 |
| EP1575621A2 (en) | 2005-09-21 |
| AU2003295442A1 (en) | 2004-07-09 |
| US20050025711A1 (en) | 2005-02-03 |
| US7250153B2 (en) | 2007-07-31 |
| CY1110105T1 (el) | 2015-01-14 |
| CA2509035C (en) | 2011-07-19 |
| KR101067159B1 (ko) | 2011-09-22 |
| WO2004054637A2 (en) | 2004-07-01 |
| NO20053343D0 (no) | 2005-07-08 |
| IL169119A (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ165595A3 (en) | Aqueous injectable preparation for radiodiagnosis | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| WO2012148850A2 (en) | Radiopaque injectable nucleus hydrogel compositions | |
| Frenzel et al. | Characterization of a novel hafnium-based x-ray contrast agent | |
| JP2008542260A (ja) | 新規の注射可能組成物及びその調製方法 | |
| TWI500421B (zh) | Pharmaceutical composition | |
| EP1725268B1 (en) | X-ray contrast formulation comprising a mixture of iodinated monomer and dimer | |
| JP2008516967A (ja) | 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物 | |
| JP3672342B2 (ja) | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル | |
| JP3552240B2 (ja) | 高濃度ｔｃｆ製剤 | |
| AU718356B2 (en) | A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs | |
| JP2006509841A (ja) | 生物学的許容量が改善された造影剤配合物 | |
| JPH075456B2 (ja) | 点眼液 | |
| CN1290506C (zh) | 药物组合物 | |
| WO2002038151A1 (fr) | Compositions permettant de reduire la concentration de peroxydes lipidiques | |
| JP7421770B2 (ja) | 保存安定性に優れた医薬組成物 | |
| JP6082405B2 (ja) | Ｘ線診断用組成物の安定化 | |
| EP1792894B1 (en) | Contrast agents | |
| KR101169478B1 (ko) | 용액 의약조성물 | |
| US20240238275A1 (en) | Hydromorphone formulations for multi-dose products | |
| US20020065263A1 (en) | Formulation | |
| OA16267A (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061026 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20070704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070704 |